Following today’s DOJ legal action aimed at blocking the proposed combination of Optum and Amedisys, Optum has issued the following statement:
The Amedisys combination with Optum would be pro-competitive and further innovation, leading to improved patient outcomes and greater access to quality care. We will vigorously defend against the DOJ’s overreaching interpretation of the antitrust laws.
Additional information is available here.
Share This Story